Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

Follicular lymphoma (FL) is the most common indolent B-cell lymphoma in western countries. Overall, 70% of patients achieve complete remission after first treatment.[1][1] However, it is characterized by a pattern of relapsing and remitting disease. The outcome of patients with FL has clearly

[1]  L. Staudt,et al.  Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. , 2015, The Lancet. Oncology.

[2]  İrfan Yavaşoğlu,et al.  Follicular Lymphoma , 2015, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[3]  P. Kao,et al.  Update on Diagnosis and Management , 2015 .

[4]  M. Federico,et al.  Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial , 2014, Clinical Cancer Research.

[5]  Annibale Versari,et al.  Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. , 2014, The Lancet. Haematology.

[6]  A. Freedman,et al.  Follicular lymphoma: 2014 update on diagnosis and management , 2014, American journal of hematology.

[7]  Summer S. Han,et al.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.

[8]  M. Federico,et al.  The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Angrilli,et al.  R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Jardin,et al.  Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3′ BCL2 breakpoints and evidence of a new cluster , 2000, Leukemia.

[12]  J. Gribben,et al.  Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. , 1993, Blood.